This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that very small increments are hard to measure accurately with a syringe.
It took me longer than it should have to see that.
Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.
On balance I think that is right, and I would not bet much on it.
Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.
I would treat that as a working assumption and revisit it.
Post #30 describes the usual case. This is about the unusual one.
Split dosing within a week is sometimes proposed to smooth tolerability. With a week-long half-life the concentration is already smooth, so what it would change is the timing of the peak rather than its existence.
Sensible. I would want the same detail before I acted on it either.
How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.
Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.
Written quickly, so the reasoning may be tighter than the wording.
The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.
I have written this out at length because the short version keeps being misread.
Taking post #36 at face value and following it one step further.
The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.
The number is defensible. The precision I gave it is not.
Post #38 and I disagree about the size of the effect, not about the direction.
Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.
Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.
The reasoning is more useful than the number, which is why I have shown it.
Answering the question post #39 raises rather than the one it answers.
Research-use-only material is not a licensed product and no labelling covers it. Everything in this subcategory about published schedules describes what was done in trials of licensed formulations.
Taking post #43 at face value and following it one step further.
If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.
I would want a second opinion before relying on that.
Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.
That much is documented. The rest is how I have interpreted it.
Worth separating two things that post #48 runs together.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
I would rather say I do not know than round it up to an answer.
A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.
When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
Post #50 is right about the mechanism and I think understates the practical bit.
Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.
That is a description of practice, not a recommendation of it.
Coming back to post #52, because the follow-up matters more than the original answer.
Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.
It is one reading of the data and not the only reasonable one.
Post #54 answers the question as asked. The question underneath it is different.
Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and both halves of that should be said.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.
Adding the measurement that post #58 says would settle it.
Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.
Somebody will have a better source than mine, and I hope they post it.
Post #57 describes the usual case. This is about the unusual one.
Nothing here is medical advice, and a titration question is one of the few where a prescriber can genuinely answer in a minute what a thread will take a week to circle.
It is worth stating the boring hypothesis before the interesting one.